March, 2021
The Dolaflexin-based antibody-drug conjugate XMT-1536 targets the solid tumor lineage antigen SLC34A2/NaPi2b
March, 2021
Safety and Efficacy of XMT-1536 in Ovarian Cancer: A Subgroup Analysis from the Phase 1 Expansion Study of XMT-1536, a NaPi2b Antibody-Drug Conjugate
September, 2020
Phase 1 expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)
May, 2020
A Phase 1 study of XMT-1536 in patients with solid tumors likely to express NaPi2b: A summary of dose escalation
May, 2020
NaPi2b Expression in a Large Surgical Non-Small Cell Lung Cancer (NSCLC) Cohort
October 2019
Mersana’s Innovative ADC Platforms – World ADC Summit 2019
October 2019
Phase 1 dose escalation study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC), in patients (pts) with solid tumors likely to express NaPi2b
June 2019
Dolasynthen: A Novel, Homogeneous Auristatin F Hydroxypropyl Amide Antibody-Drug Conjugate Platform
April 2019
Target Expression/Efficacy Relationship of XMT-1522, a HER2-targeting Antibody Drug Conjugate (ADC), in an Unselected Series of Non-small Cell Lung Cancer (NSCLC) Primary Human Carcinoma Xenografts.
November 2018